Patent intelligence · US
US 11077241
Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid
Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combinat…
Patent details — US 11077241
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 3, 2021
- Expiration
- Jul 29, 2041
- Applicant
- RegenLab USA LLC
- Claims
- 17
- CPC classes
- A61K, A61K35/16, A61K35/28, A61K35/35
Quick answer
US 11077241 (Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid) is held by RegenLab USA LLC. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RegenLab USA LLC
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K35/16, A61K35/28, A61K35/35, A61P, A61P1/02
More from RegenLab USA LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11077241?
US 11077241 (Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid) is held by RegenLab USA LLC. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11077241?
RegenLab USA LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11077241 expire?
Our index shows an expiration date of Jul 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.